October 2025 Publications
- Evidence required to evaluate the use of bacteriologically confirmed asymptomatic tuberculosis disease as a primary endpoint in prevention of tuberculosis disease vaccine licensure trials. White RG, Churchyard GJ, Horton KC, Fiore-Gartland A, Behr MA, Clark RA, Cobelens F, Ernst JD, Esmail H, Garcia-Basteiro AL, Hadinegoro SR, Hanekom WA, Hatherill M, Hill PC, Muloiwa R, Pelzer PT, Rangaka L, Rees H, Schrager L, Stanley M, Tufet M, Wong EB, Houben RMGJ. Lancet Respir Med. 2025 Oct;13(10):933-942. doi: 10.1016/S2213-2600(25)00164-X. Epub 2025 Jul 3.
- Overview of the tuberculosis vaccine development landscape. Velayutham B. Indian J Tuberc. 2025 Oct;72(4):517-520. doi: 10.1016/j.ijtb.2025.01.004. Epub 2025 Jan 19.
- Enhancing Mycobacterium tuberculosis-Ag85B immunogenicity by fusing with human Fcγ1 (Ag85B:hFcγ1). Bahrami H, Mosavat A, Soleimanpour S, Farsiani H, Valizadeh N, Rezaee SA, Amini AA. Microb Pathog. 2025 Oct;207:107894. doi: 10.1016/j.micpath.2025.107894. Epub 2025 Jul 10.
- Mn and Zn-Doped Multivariate Metal-Organic Framework as a Metalloimmunological Adjuvant to Promote Protection Against Tuberculosis Infection. Howlett TS, Kumari S, Ehrman RN, Masson J, Izzo L, Wang T, Gull H, Trashi I, Tang W, Trashi O, Satish N, Wijesundara YH, Herbert FC, Izzo AA, Gassensmith JJ. Adv Healthc Mater. 2025 Oct;14(26):e2402358. doi: 10.1002/adhm.202402358. Epub 2024 Dec 8.
- Recent advances in research on Mycobacterium tuberculosis virulence factors and their role in pathogenesis. Sun MR, Xing JY, Li XT, Fang R, Zhang Y, Li ZL, Song NN. J Microbiol Immunol Infect. 2025 Oct;58(5):497-507. doi: 10.1016/j.jmii.2025.03.017. Epub 2025 Mar 27.
- Single cell transcriptional analysis of human adenoids identifies molecular features of airway microfold cells. Alvarez-Arguedas S, Mazhar K, Wangzhou A, Sankaranarayanan I, Gaona G, Lafin JT, Mitchell RB, Price TJ, Shiloh MU. Mucosal Immunol. 2025 Oct;18(5):1199-1217. doi: 10.1016/j.mucimm.2025.07.006. Epub 2025 Jul 26.
- Targeting infection-specific peptides in immunopeptidomics studies for vaccine target discovery. Leddy O, Yuki Y, Carrington M, Bryson BD, White FM. J Exp Med. 2025 Oct 6;222(10):e20250444. doi: 10.1084/jem.20250444. Epub 2025 Jul 21.
- The impact of interferon-γ pathway on trained immunity induction by vaccination with Bacille Calmette-Guérin. Isachesku E, Cismaru A, Matzaraki V, Moorlag SJCFM, Mourits VP, Koeken VACM, de Bree LCJ, Joosten LAB, Berindan-Neagoe I, Netea MG. Sci Rep. 2025 Oct 6;15(1):34698. doi: 10.1038/s41598-025-16350-5.
- A BCG-boosting subunit vaccine RS2/DMI induces Th1-polarized immunity by targeting RD6 and secretory antigens of Mycobacterium tuberculosis. Wang X, Zhong Q, Xu Y, Liu X. Arch Microbiol. 2025 Oct 6;207(11):290. doi: 10.1007/s00203-025-04481-2.
- Th9 cells provide protective TB immunity. Xia M, Blazevic A, Ning H, Eickhoff CS, Storer CE, Head RD, Liu J, Jarvela J, Stoeckel D, Rakey E, Tennant J, Miller DL, Holloway KR, Silver RF, Hoft DF. Front Immunol. 2025 Oct 6;16:1581286. doi: 10.3389/fimmu.2025.1581286.
- Exploring γδ T-Cell Responses in Malaria and Tuberculosis: Implications for Immunity, Coinfection, and Disease Management. Mohamud YN, Chaijaroenkul W, Na-Bangchang K. Am J Trop Med Hyg. 2025 Oct 7:tpmd250316. doi: 10.4269/ajtmh.25-0316. Epub ahead of print.
- Assembly of the Mycobacterium tuberculosis type VII ESX-1 secretion system in Mycobacterium smegmatis identifies a new transcriptional activator of esx-1 genes and a novel TB vaccine. Zriba S, Lim ZL, Snider M, Niroula N, Hardouin M, Chen JM. Microbiol Spectr. 2025 Oct 7;13(10):e0113125. doi: 10.1128/spectrum.01131-25. Epub 2025 Sep 12.
- Development and preclinical evaluation of next-generation ΔsigH-based live candidate vaccines. Arora G, Munson CW, Ahmed M, Shivanna V, Devi A, Devireddy VS, Antony B, Hall-Ursone S, Gonzalez OD, Dick EJ Jr, Jagannath C, Alvarez X, Mehra S, Khader SA, Singh DK, Kaushal D. JCI Insight. 2025 Aug 28;10(19):e195947. doi: 10.1172/jci.insight.195947.
- Rv2647-Mediated NLRP3 Ubiquitination Inhibits Macrophage Pyroptosis and Promotes Mycobacterium tuberculosis Survival. Jin X, Yan H, Chen X, Feng J, Li G, Yao J, Du X, Feng G. ACS Infect Dis. 2025 Oct 10;11(10):2739-2753. doi: 10.1021/acsinfecdis.5c00192. Epub 2025 Oct 1.
- CD8+ lymphocytes in immunity against tuberculosis. Li J, Simonson AW, Flynn JL. J Immunol. 2025 Oct 10:vkaf268. doi: 10.1093/jimmun/vkaf268. Epub ahead of print.
- Diagnostic value of five Mycobacterium tuberculosis dormant highly expressed antigens in latent infections and immunogenicity assessment of a novel subunit vaccine PB2-DIMQ. Zhong Q, Wang X, Xu Y, Wang R, Zhou M, Liu X. Tuberculosis (Edinb). 2025 Oct 14;155:102698. doi: 10.1016/j.tube.2025.102698. Epub ahead of print.
- Single-Cell Transcriptomics Reveals Depletion and Dysregulation of Mycobacterium tuberculosis-Specific Th1 and Th17 Cells Early After Acquisition of Human Immunodeficiency Virus. Pearson RA, Krish KN, Whatney WE, Jaoko W, Mandaliya K, Overbaugh J, Graham SM, McClelland RS, Hicks SL, Maurer J, Scharer CD, Day CL. J Infect Dis. 2025 Oct 15;232(4):835-846. doi: 10.1093/infdis/jiaf354.
- Enhanced immunogenicity in mouse by recombinant BCG prime and protein boost based on latency antigen Rv1733c and/or reactivation antigen RpfE. Ashayeripanah M, Kazemi B, Saubi N, Joseph-Munne J, Eftekhar F. BMC Infect Dis. 2025 Oct 16;25(1):1338. doi: 10.1186/s12879-025-11534-w.
- Recombinant Mycobacterium smegmatis expressing antigen 85B for immunotherapy of Mycobacterium tuberculosis-infected mice. Chang Y, Ning H, Liang X, Lu Y, Kang J, Li X, Liu S, Hao L, Ma Y, Zhang F, Bai Y. Hum Vaccin Immunother. 2025 16 Oct. doi: 10.1080/21645515.2025.2571287. Epub 2025 Oct 16. Online ahead of print.
- Protective Effect and Immune Mechanism of EPCP009 Booster Immunization after BCG Prime Immunization Against Tuberculosis in Mice – China, 2024. Wang R, Fan X, Li M, Zhao X, He X, Wan K, Liu H. China CDC Wkly. 2025 Oct 17;7(42):1329-1336. doi: 10.46234/ccdcw2025.225.
- Targeting HspX of Mycobacterium tuberculosis: Advances in diagnostics, treatment, and vaccine development. Hidalgo-Gajardo A, Mangui B, Villavicencio C, Toledo JR, Camacho F. Tuberculosis (Edinb). 2025 Oct 22;155:102702. doi: 10.1016/j.tube.2025.102702. Epub ahead of print.
- Safety of intradermal Danish- vs. transcutaneous Tokyo-strain BCG vaccination in Korean children: A nationwide cohort study. Lee YH, Gwak E, Kang HM, Choe YJ, Choi YY, Kim KJ, Kang CR, Choi WS, Noh JY, Choi NK, Jeong NY, Lee JK. Vaccine. 2025 Oct 24;65:127828. doi: 10.1016/j.vaccine.2025.127828. Epub 2025 Oct 3.
- Co-administration of a synthetic saccharide conjugate vaccine with BCG provides synergistic protection against murine tuberculosis. Miranda-Hernandez S, Sathkumara HD, Zhao G, Schofield L, Kupz A. Vaccine. 2025 Oct 29;68:127912. doi: 10.1016/j.vaccine.2025.127912. Epub ahead of print.
- Vaccine confidence and potential implications for new tuberculosis vaccines. Hesketh ZM, Clark RA, Limaye R, Pelzer PT, Palmer S, White RG. BMC Glob Public Health. 2025 Oct 31;3(1):96. doi: 10.1186/s44263-025-00216-z.